Self-Assembling Peptide Nanofibers Eliminated Established HPV Tumors in Mice by Boosting Anti-Cancer Immunity | Research

The takeaway

Peptide nanofibers carrying an HPV cancer antigen abolished established tumors in up to 67% of mice and outperformed unassembled peptides by generating potent cancer-killing T-cell responses.

66.7% tumor-free
Nanofiber vaccination eliminated established 2-3 mm HPV tumors in two-thirds of mice, with 50% cure rate even for larger 5-6 mm tumors

What the researchers found

The HPV16 E7 peptide (residues 44-62) was attached to the self-assembling peptide Q11 to create nanofibers used in two vaccination strategies:

Preventive: Nanofiber immunization almost completely suppressed TC-1 tumor growth and even prevented tumor re-establishment after a 6-week rest period

Therapeutic:

- 66.7% tumor-free rate in mice with 2-3 mm established tumors

- 50% tumor-free rate in mice with larger 5-6 mm tumors

- Significantly increased effector Th1 cells, cytotoxic T lymphocytes (CTLs), IFN-γ, and TNF-α

- Reduced Th2 cells, myeloid-derived suppressor cells (MDSCs), and IL-4 compared to controls

- Nanofibers outperformed unassembled peptides for treating larger established tumors

Why it matters

Existing HPV vaccines (Gardasil, Cervarix) prevent infection but cannot treat existing HPV cancers. Therapeutic HPV vaccines have shown disappointing clinical results, largely because they fail to generate strong enough T-cell responses to overcome the tumor's immune-suppressive environment. This nanofiber approach addresses both problems: the self-assembling structure naturally enhances immune activation (no separate adjuvant needed), and the resulting immune response is strong enough to eliminate established tumors in a significant fraction of animals.

How the study worked

HPV16 E744-62 peptide was chemically conjugated to the N-terminus of the self-assembling peptide Q11. The conjugates formed nanofibers and were used to immunize C57BL/6 mice in a TC-1 tumor graft model. Two strategies were tested: preventive (immunization before tumor challenge) and therapeutic (immunization after tumors were established at 2-3 mm or 5-6 mm). Immune responses were evaluated by measuring Th1/Th2 cells, CTLs, MDSCs, IFN-γ, TNF-α, and IL-4 in E7 peptide-stimulated splenocytes. Tumor growth and tumor-free survival were tracked.

What this study cannot tell us

This is a mouse study using a transplanted tumor model (TC-1), which does not fully replicate human HPV-related cancers that develop over years within an immunosuppressive microenvironment. The TC-1 model is relatively immunogenic, which may overestimate vaccine efficacy. Sample sizes per group are not specified in the abstract. No human safety or efficacy data exist. The long-term durability of the immune response is only partially addressed (6-week re-challenge). Manufacturing and stability challenges for nanofiber vaccines are not discussed.

How to read the evidence

This is a preclinical animal study using a well-established mouse tumor model. The results are strong with clear dose-response effects and immune mechanism characterization, but translation to human HPV cancers is unproven. Evidence level is preclinical with promising therapeutic efficacy.

When this study was published

Published in 2019, this study contributed to the growing body of evidence for self-assembling peptide nanofiber vaccines. The Q11 platform and related self-assembling peptide systems continue to be developed for multiple vaccine applications.

The bigger picture

Self-assembling peptide nanofibers are an emerging platform for vaccine delivery that eliminates the need for traditional adjuvants, which can cause inflammation and side effects. The Q11 peptide system used here has been studied with multiple antigens and represents a modular vaccine platform — different disease targets can be attached to the same self-assembling backbone. For HPV-related cancers specifically, this addresses a major unmet need: while preventive vaccines exist, millions of people already infected with HPV have no effective immunotherapy options.

Questions still open

Could this nanofiber vaccine approach work in human HPV-related cancers, where tumors are typically larger and more immune-suppressive than in mouse models?
Would combining nanofiber vaccination with checkpoint inhibitors further improve tumor elimination rates?
Can the Q11 nanofiber platform be adapted for other cancer antigens beyond HPV E7?

Common questions

How do self-assembling peptide nanofibers work as a vaccine?

The Q11 peptide naturally arranges itself into tiny fibers when dissolved in salt water. When a cancer antigen (the HPV E7 peptide) is attached to Q11, it gets incorporated into these nanofibers. The fibrous structure is naturally recognized by the immune system as something foreign, triggering a strong immune response without needing traditional chemical adjuvants. The nanofibers essentially act as both the antigen carrier and the immune-stimulating agent in one simple, self-assembling package.

Why can't existing HPV vaccines treat HPV cancers?

Current HPV vaccines (like Gardasil) use virus-like particles to generate antibodies that prevent initial HPV infection. But once HPV has already infected cells and caused cancer, antibodies aren't enough — you need killer T-cells that can recognize and destroy the cancer cells from the inside. Therapeutic vaccines like this nanofiber approach are specifically designed to activate these cancer-killing T-cells rather than antibodies, targeting proteins that the cancer cells display on their surface.

Read the original research

Self-Assembled Nanofibers Elicit Potent HPV16 E7-Specific Cellular Immunity And Abolish Established TC-1 Graft Tumor.

International journal of nanomedicine, 14, 8209-8219

View on PubMed ↗Publisher’s paper ↗

Citation

Li, Sijin; Zhang, Qishu; Bai, Hongmei; Huang, Weiwei; Shu, Congyan; Ye, Chao; Sun, Wenjia; Ma, Yanbing. (2019). Self-Assembled Nanofibers Elicit Potent HPV16 E7-Specific Cellular Immunity And Abolish Established TC-1 Graft Tumor.. International journal of nanomedicine, 14, 8209-8219. https://doi.org/10.2147/IJN.S214525